Sotera Health Company
SHC Healthcare Diagnostics & Research
Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024. In the quarter to June 2026, revenue grew 9.18%, EPS grew 533.3%, free cash flow grew 60.6% and total debt fell 3.54%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow SHC
Sotera Health Company (SHC) EV/Sales
As of 16 October 2026, Sotera Health Company (SHC) trades at a EV/Sales of 5.7×. Over the past ten years it has ranged from 3.3× (November 2022) to 11.8× (December 2020); the current reading is higher than 37% of that period. That is in line with the Diagnostics & Research industry median of 5.5× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.9× | 10.41% |
| FY2024 | 5.4× | (15.34%) |
| FY2023 | 6.3× | 61.62% |
| FY2022 | 3.9× | (55.77%) |
| FY2021 | 8.9× | (16.80%) |
| FY2020 | 10.7× | (2.55%) |
| FY2019 | 10.9× | 0.00% |
| FY2018 | 10.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.7× | 13.19% |
| Mar 2026 | 5.0× | (14.86%) |
| Dec 2025 | 5.9× | 6.46% |
| Sep 2025 | 5.6× | 21.90% |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RDNT RadNet, Inc. compare | 2.6× |
| QGEN QIAGEN N.V. compare | 4.9× |
| VCYT Veracyte, Inc. compare | 5.3× |
| SHC Sotera Health Company | 5.7× |
| CDNA CareDx, Inc. compare | 6.4× |
| BLLN BillionToOne, Inc. compare | 10.3× |
| ADPT Adaptive Biotechnologies Corporation compare | 12.4× |
| TWST Twist Bioscience Corporation compare | 18.8× |
| GRAL GRAIL, Inc. compare | 25.5× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)